denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: 506. Bone Marrow Microenvironment: Poster II
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Biological Processes, Microbiome, Technology and Procedures, Imaging, Omics technologies
Acute myeloid leukemia (AML) resides in an immune rich microenvironment. A comprehensive understanding of leukemic cells and their interactions within the leukemic bone marrow microenvironment is needed to better understand disease biology. Recent high-plex proteomics technologies have been developed to interrogate the tumor immune microenvironment, however, these systems suffer from several challenges when being applied in the context of leukemic bone marrow tissue. To address this, we optimized a high throughput bone marrow tissue-microarray based pipeline for high-plex spatial proteomics imaging in bone marrow that reliably captures the immune, tumor, and structural components of the bone marrow microenvironment at the single cell level resolution using both immunofluorescence (IF) and imaging mass cytometry (IMC) on a single slide.
Methods
As a proof-of-concept, we organized 16 bone marrow biopsies from 7 adult AML patients into 2 tissue microarrays using 1.5 mm diameter cores with a 4 µm section thickness. Each TMA was then imaged using the COMET multiplex IF platform with a 28-plex panel covering canonical markers for immune cells (n=4), AML cells (n=12), and functional markers (n=12). Using the same slide, we then performed IMC with a 25-plex panel containing 16 overlapping markers to assess concordance between methodologies for a total of 34 unique proteins imaged. Image alignment was guided by tissue structure and co-expression of shared markers onto a reference H&E-stained serial section, which provided structural components such as trabecular bone. Cells were segmented using the convolutional neural network U-Net and manually phenotyped by mean intensity thresholds. Unbiased clustering over each cell’s spatial K function was performed to identify 5 distinct regions of cellular organization. We then validated the results of our spatial workflow by staining adjacent sections using the Opal 7-color multiplex IF protocol. Gene set enrichment was performed on an integrated AML transcriptomic dataset consisting of patients from TCGA, MDACC, and BEAT-AML studies (n=480) using a published TLS signature (Cabrita et. al. Nature 2020) to assess prognostic ability.
Results
Clustering over the spatial K function revealed 5 regions enriched in AML cells, monocyte/macrophage lineage cells, lymphocytes, unlabeled cells, and one region that contained a relatively even mix of all cell types. Interestingly, we observed the lymphocyte enriched region to only appear in 3 of the 16 tumor cores, taking the form of a dense aggregate of B and T cells, similar in structure and organization to tertiary lymphoid structures (TLS) in solid cancers. B cells in these aggregates displayed increased expression of Ki-67, suggesting proliferating B cells analogous to germinal centers. Furthermore, in tumor cores where these aggregates appeared, we found significant enrichment of monocyte and macrophage lineage cells (p=0.0164), as well as increased CD4 (p=0.017) and CD8 (p=0.041) T cell infiltration into areas of high AML cell density. Finally, we were able to validate the presence of these TLS-like aggregates by staining adjacent sections of the two TMAs using the Opal 7-color multiplex IF protocol.
We sought to further investigate the presence of TLS-like aggregates in AML by querying large public datasets with a previously validated TLS signature (Cabrita et. al. Nature 2020). Interestingly, the TLS signature strongly correlated to hypoxia, inflammation, and angiogenesis hallmark gene sets, aligning with the propensity of TLSs to form in inflammatory conditions and promote vessel growth in solid cancers. Furthermore, when dichotomizing patients by median TLS score, we found that the signature significantly correlated with overall survival (p=0.016).
Conclusions
We find that by utilizing the strengths of both high-plex IF and IMC in our integrative sample-to-analysis workflow, we can reliably spatially characterize the immune, tumor, and structural elements in the bone marrow microenvironment, allowing us to uncover novel cellular structures such as TLS-like aggregates and characterize their effect on the leukemic bone marrow microenvironment. Further, our study's methodologies can be adapted for other bone marrow diseases where decalcification and autofluorescence present challenges.
Disclosures: Veletic: Avilect Biosciences: Research Funding; Aviceda Therapeutics: Research Funding. Dasdemir: Phenomic AI: Membership on an entity's Board of Directors or advisory committees; PBM Capital: Membership on an entity's Board of Directors or advisory committees; Osteologic: Membership on an entity's Board of Directors or advisory committees; Oncolytics: Membership on an entity's Board of Directors or advisory committees; Matrisome: Membership on an entity's Board of Directors or advisory committees; Marker Therapeutics: Membership on an entity's Board of Directors or advisory committees; Lytix Biopharma: Membership on an entity's Board of Directors or advisory committees; LAVA Therapeutics: Membership on an entity's Board of Directors or advisory committees; InterVenn Biosciences: Membership on an entity's Board of Directors or advisory committees; ImaginAb: Membership on an entity's Board of Directors or advisory committees; Hummingbird: Membership on an entity's Board of Directors or advisory committees; Henlius/Hengenix: Membership on an entity's Board of Directors or advisory committees; Glympse: Membership on an entity's Board of Directors or advisory committees; Enable Medicine: Membership on an entity's Board of Directors or advisory committees; Earli Inc: Membership on an entity's Board of Directors or advisory committees; Dragonfly Therapeutics: Membership on an entity's Board of Directors or advisory committees; C-Reveal Therapeutics: Membership on an entity's Board of Directors or advisory committees; Catalio: Membership on an entity's Board of Directors or advisory committees; Candel Therapeutics: Membership on an entity's Board of Directors or advisory committees; BioAtla LLC: Membership on an entity's Board of Directors or advisory committees; Asher Bio: Membership on an entity's Board of Directors or advisory committees; Apricity: Membership on an entity's Board of Directors or advisory committees; Akoya Biosciences: Membership on an entity's Board of Directors or advisory committees; Affini-T: Membership on an entity's Board of Directors or advisory committees; Achelois: Membership on an entity's Board of Directors or advisory committees; Time Bioventures: Other: Private Investment; Sporos: Other: Private Investment; JSL Health: Other: Private Investment; BioNTech: Other: Private Investment; Adaptive Biotechnologies: Other: Private Investment; Illumina: Other: Research Support; Polaris Pharma: Membership on an entity's Board of Directors or advisory committees; Spotlight: Membership on an entity's Board of Directors or advisory committees; Trained Therapeutix Discovery: Membership on an entity's Board of Directors or advisory committees; Two Bear Capital: Membership on an entity's Board of Directors or advisory committees; Xilis,Inc.: Membership on an entity's Board of Directors or advisory committees. Abbas: Molecular Partners: Consultancy; GlaxoSmithKline: Research Funding; Genentech: Research Funding; Alamar Biosciences: Honoraria; Enzyme By Design: Research Funding; Blueprint Medicines Corporation: Research Funding; Illumina: Honoraria, Other: Inkind Support, Research Funding; Ascentage: Research Funding.